Key facts
- This page summarizes Nir Sassi's Form 4 filing for Indaptus Therapeutics, Inc. (INDP).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 23 Jan 2024, 16:15.
Nir Sassi - 22 Jan 2024 Form 4 Insider Report for Indaptus Therapeutics, Inc. (INDP)
- Form type
- 4
- Accepted by SEC
- 23 Jan 2024, 16:15:47 UTC
- Previous filing
- 20 Jan 2023
- Next filing
- 10 Oct 2024
- SEC filing
- View on sec.gov
- Reporting owner signature
- /s/ Nir Sassi
Source evidence
5 source fields
Reporting owner
1 detail
Key filing fact
Nir Sassi filed Form 4 for Indaptus Therapeutics, Inc. (INDP) on 23 Jan 2024.
Change
- Previous filing in this sequence was filed on 20 Jan 2023.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
See Original Filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
INDP
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +40,000
- Change %
- Price
- $0.000000
- Shares after
- 40,000
- Date
- 22 Jan 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 40,000
- Exercise price
- $1.74
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
The stock option vests and becomes exercisable as to one-third of the total shares on January 22, 2025 and thereafter in equal quarterly installments over the following 24 months, such that the stock option becomes vested and exercisable as to all shares on January 22, 2027.